The National Institute of Pharmaceutical R&D (Beijing) has described bridged heterocyclyl-substituted pyrimidine compounds acting as tyrosine-protein kinase JAK-1 and/or non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of inflammation, autoimmune disease and cancer.
Shionogi & Co. Ltd. has in-licensed Japan rights to Grunenthal GmbH’s intra-articular injectable, resiniferatoxin, for the treatment of pain associated with osteoarthritis of the knee. Currently in phase III trials, RTX is a transient receptor potential vanilloid 1 agonist, which can reversibly desensitize TRPV1-expressing nociceptors. This mechanism may result in long-lasting pain relief.
Shionogi & Co. Ltd. has in-licensed Japan rights to Grunenthal GmbH’s intra-articular injectable, resiniferatoxin, for the treatment of pain associated with osteoarthritis of the knee. Currently in phase III trials, RTX is a transient receptor potential vanilloid 1 agonist, which can reversibly desensitize TRPV1-expressing nociceptors. This mechanism may result in long-lasting pain relief.
Gilead Sciences Inc. has bought the privately owned U.K. biotech Mirobio Ltd., paying $405 million for the Oxford-based firm and its checkpoint agonists to treat autoimmune diseases. Foster City, Calif.-based Gilead will gain Mirobio’s discovery platform and entire portfolio of immune inhibitory receptor agonists.
A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens up a previously unexplored field of research in the molecular and cellular mechanisms triggered after death, an area of potential significance, since it covers different biological processes with multiple applications.
Inventisbio Co. Ltd. has raised ¥2.084 billion (US$296 million) in an IPO on Shanghai’s STAR Market priced at ¥18.12 per share, though its stock saw a disappointing debut, opening at ¥14 per share on the first trading day July 25 and closing at $15.29, for a drop of 15.6%. The stock closed Aug. 1 at ¥14.42.
Apollo Therapeutics Group Ltd. has bought worldwide rights to Avalo Therapeutics Inc.’s anti-IL-18 antibody, camoteskimab, in a deal worth up $89 million, taking on development of the early stage drug for arthritis and potentially other diseases.
Inventisbio Co. Ltd. has raised ¥2.084 billion (US$296 million) in an IPO on Shanghai’s STAR Market priced at ¥18.12 per share, though its stock saw a disappointing debut, opening at ¥14 per share on the first trading day July 25 and closing at $15.29, for a drop of 15.6%. The stock closed Aug. 1 at ¥14.42.
South Korea’s Medipost Co. Ltd. is gearing up for phase III trials in the U.S. of its stem cell therapy, Cartistem, an allogeneic human umbilical cord blood-derived mesenchymal stem cell therapy for treatment of knee articular damage in patients with osteoarthritis.
RSS
